Rapport Therapeutics, Inc. RAPP
25.85 USD -1.17 (-4.33%)
At closeNov 12, 2026, 4:01 PM EST
25.85 0.00 0.00%
After hours · Nov 12, 4:01 PM ET
25.45 Day range 26.90
22.06 52-week range 52.93
- YTD
- -14.80%
- 1 year
- +2.70%
News
investorplace.com Insider Buying Signals: 3 Healthcare Stocks to Watch Insider buying and share buybacks have put Prothena, Rapport Therapeutics and Azenta on the radar. See the catalysts and risks behind each stock.
benzinga.com UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64 UBS analyst Joon Lee maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $71 to $64.- benzinga.com Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66 Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.
benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.
benzinga.com Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.19) by 29.41 percent. This is a 18.31 percent decrease over losses…- benzinga.com Rapport Therapeutics Closes Underwritten Public Offerings Of 9,761,905 Shares At $21.00 Per Share Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
benzinga.com Enphase Energy Posts Downbeat Q3 Results, Joins NXP Semiconductors, Seagate And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed as Enphase plunges 17% after earnings and weak guidance; Rapport, Intapp, Logitech and others also fall premarket.
benzinga.com Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032 Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the "Investor"), in a separately negotiated transaction (the "concurrent private
benzinga.com Why Ultra Clean Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Ultra Clean shares surged 14.6% after beating earnings and sales estimates; Ultralife soared 143.8% on a $320M acquisition deal.
benzinga.com Rapport Therapeutics (RAPP) Shares Sink 20% After Hours Rapport Therapeutics stock falls after hours as investors assess proposed stock and convertible notes offerings.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
- benzinga.com Rapp Therapeutics Files For Offering Of Common Stock; Size Not Disclosed Common StockWe are offering $ of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.Our common stock is listed on The Nasdaq Global Market under the…
- benzinga.com Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
- benzinga.com Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82 Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
- benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.
benzinga.com Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70 Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.
benzinga.com HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.
benzinga.com Why Is Rapport Therapeutics Stock Trading Higher Today? Rapport Therapeutics posts positive Phase 2 trial results for RAP-219 in acute bipolar mania, setting up Phase 3 studies in 2027.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.- benzinga.com Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
- benzinga.com UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71 UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $71.
- benzinga.com Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50 Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $50.
benzinga.com Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65 Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
benzinga.com Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.- benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.
- benzinga.com BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66 HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.
- benzinga.com BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
- benzinga.com Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses…
- benzinga.com BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
benzinga.com Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52 Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $52.- benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $53 to $65.
- benzinga.com Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56 Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and raises Price Target to $56.
- benzinga.com BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $53 price target.
- benzinga.com Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.65) by 35.38 percent. This is a 38.24 percent increase over losses…
benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $53 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $47 to $53.- benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Raises Price Target to $46 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and raises the price target from $43 to $46.
- benzinga.com Rapport Therapeutics Files Shelf Registration To Offer Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In Future Offerings; No Terms Disclosed Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or more series or classes, our common stock, preferred stock, debt securities, warrants and/or units, in…
- benzinga.com Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.69) by 5.11 percent. This is a 26.32 percent decrease over losses…
benzinga.com Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner, with FDA filing planned for 2026.
benzinga.com This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Wells Fargo Initiates Coverage On Rapport Therapeutics with Overweight Rating, Announces Price Target of $43 Wells Fargo analyst Benjamin Burnett initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Overweight rating and announces Price Target of $43.
- benzinga.com Rapport Therapeutics Plans to Initiate Its Phase 3 Program for RAP-219 in Focal Onset Seizures in Q2 of 2026 and Expand Its Epilepsy Portfolio With New Program in Primary Generalized Tonic-Clonic Seizures CLINICAL AND PIPELINE UPDATESRapport is prioritizing programs it believes have the greatest potential to deliver meaningful impact for patients and long-term value for the Company. This disciplined…
- benzinga.com HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $40 HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $34 to $40.
- benzinga.com Rapport Therapeutics Announces New Data And Post Hoc Analysis On Clinical And Patient Reported Benefits Of RAP-219 In Drug-Resistant FOS, Alongside Topline Efficacy And Safety Data From Phase 2a FOS Trial Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of…
benzinga.com This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday